Page last updated: 2024-08-22

zirconium and everolimus

zirconium has been researched along with everolimus in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Jong, S; de Vries, EG; Kosterink, JG; Lub-de Hooge, MN; Pot, L; Reyners, AK; Schröder, CP; Terwisscha van Scheltinga, AG; Timmer-Bosscha, H; van der Bilt, AR; van der Zee, AG	1
Bongaerts, AH; Brouwers, AH; de Jong, JR; de Vries, EG; Fiebrich, HB; Links, TP; Lub-de Hooge, MN; Oosting, SF; Oude Munnink, TH; Sluiter, WJ; van Asselt, SJ; Walenkamp, AM	1

Other Studies

2 other study(ies) available for zirconium and everolimus

Article	Year
Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-15, Volume: 18, Issue:22 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Cell Line, Tumor; Everolimus; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zirconium	2012
Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological Transport; Chromogranin A; Everolimus; Feasibility Studies; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Radioisotopes; Sirolimus; Treatment Outcome; Vascular Endothelial Growth Factor A; Zirconium	2014

Article

Year

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-15, Volume: 18, Issue:22

Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Cell Line, Tumor; Everolimus; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zirconium

2012

Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:7

Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological Transport; Chromogranin A; Everolimus; Feasibility Studies; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Radioisotopes; Sirolimus; Treatment Outcome; Vascular Endothelial Growth Factor A; Zirconium

2014